Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival

International Journal of Biological Markers

Volumn 17, Issue 1, 2002, Pages 33-41

  Cufer, Tanja ^a   Vrhovec, I ^a   Borstnar S ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Breast cancer; Locoregional recurrence free survival; Metastasis free survival; Overall survival; PAI 1; Survival after locoregional recurrence

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; ESTROGEN; HORMONE RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1 ANTIGEN; PROGESTERONE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DISEASE MARKER; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; METASTASIS; MULTIVARIATE ANALYSIS; PROGNOSIS; QUANTITATIVE ANALYSIS; RELAPSE; STATISTICAL SIGNIFICANCE; TISSUE LEVEL; TUMOR CLASSIFICATION; TUMOR VOLUME;

EID: 0036220929     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.4665     Document Type: Article

References (39)

1. Locoregional recurrence after mastectomy or breast-conserving therapy
2. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy
3. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: Results from a randomized trial. Investigators of the Ontario Clinical Oncology Group
4. Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomized trials
5. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis
6. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group
7. Local-regional recurrence in breast cancer after mastectomy and adriamycin-based adjuvant chemotherapy: Evaluation of the role of postoperative radiotherapy
8. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer
9. Modified radical mastectomy or how to achieve optimal loco-regional control in larger breast cancers
10. Risk factors in breast-conserving therapy
11. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
12. Prognostic value of p53 for local failure in mastectomy treated breast cancer patients
13. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas
14. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
15. Clinical relevance of the urokinase-type and the tissue-type plasminogen activators and their inhibitor PAI-1 in breast cancer
16. Multiparametric prognostic evaluation of biological factors in primary breast cancer
17. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
18. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 on cytosolic extracts of breast carcinomas are associated with poor prognosis
19. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
20. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer
21. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients
22. Prognostic impact of tumor biological factors on survival in node-negative breast cancer
23. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
24. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
25. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
26. Dissemination risk index based on plasminogen activator system components in primary breast cancer
27. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
28. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
29. The serpin PAI-1 inhibits cell migration by blocking integrin αv β3 binding to vitonectin
30. uPA and PAI-1 ready for routine testing in primary breast cancer: Pooled analysis (n=8.377) provides level-I evidence for clinical relevance
31. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
32. Breast-conserving therapy: Proteases as risk factors in relation to survival after local relapse
33. Grading of invasive carcinoma of the breast
34. Progesterone and progesterone receptors in experimental breast cancer
35. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts
36. Nonparametric estimation from incomplete observations
37. Regression models and life-tables
38. Urokinase type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer
39. Plasminogen activator inhibitor 1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer